We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Skeletal Muscle Biomarkers in People With Fragile Sarcolemmal Muscular Dystrophy

This study is currently recruiting participants.
Verified July 13, 2017 by National Institutes of Health Clinical Center (CC) ( Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) )
Sponsor:
ClinicalTrials.gov Identifier:
NCT01851447
First Posted: May 10, 2013
Last Update Posted: October 19, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
National Institute of Neurological Disorders and Stroke (NINDS)
National Institutes of Health Clinical Center (CC)
University of Massachusetts, Worcester
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) )
  Purpose

Background:

- Some kinds of muscular dystrophy affect the skeletal muscle membrane. In these conditions, the muscle membrane is more fragile. This affects how the muscles contract and relax, which causes movement problems. Researchers are looking at several muscle enzymes, or chemicals that affect how muscle cells function. By studying changes in these enzymes, they may be able to better understand how muscular dystrophy affects the cells. Researchers want to collect biomarkers (chemicals from blood samples) from people with fragile sarcolemmal muscular dystrophy. This information may provide better treatments for this condition.

Objectives:

- To study biomarkers that may affect the muscles of people with fragile sarcolemmal muscular dystrophy.

Eligibility:

- Individuals at least 18 years of age with fragile sarcolemmal muscular dystrophy.

Design:

  • Participants will be screened with a medical history and physical exam.
  • Participants will be asked to come for four visits to the National Institutes of Health Clinical Center. The visits will be at least 2 months apart. Each visit will require participants to stay for 5 days at the clinical center.
  • During each visit, participants will provide frequent small blood samples. These samples will be collected while at rest and after physical exercise.
  • Participants will also have a physical therapy assessment. They will perform standard motor function tests and imaging tests (MRI, MRS). These tests may take up to 1 hour each time.
  • Treatment will not be provided as part of this study.

Condition
Genetic Disorder

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Pilot Study to Assess Biomarkers of Changes in Barrier Function of Skeletal Muscle in Patients With a Fragile Sarcolemmal Muscular Dystrophy

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC) ( Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) ):

Primary Outcome Measures:
  • changes in serum enzyme, protein, cytokine and microRNA levels with both activity and time [ Time Frame: multiple assessments within each visit for 4 visits total over 3 years ]
  • changes in motor function abilities [ Time Frame: once each visit ]

Estimated Enrollment: 11
Study Start Date: May 9, 2013
Estimated Study Completion Date: February 20, 2018
Estimated Primary Completion Date: February 20, 2018 (Final data collection date for primary outcome measure)
Detailed Description:

Objectives: the aim of this protocol is to identify biomarker and clinical correlates of changes in the barrier function of skeletal muscle membrane (i.e. cell membrane permeability) before and after routine motor function testing in patients with one of the Fragile Sarcolemmal Muscular Dystrophies (FSMD).

Study population: patients with early adulthood or later onset of a FSMD (LGMD2B-F, I, L, MM, BMD, and MMD3).

Design: pilot study.

Outcome measures: increased change in baseline levels of proteins that are released into the blood from damaged skeletal muscle, such as creatine kinase (CK), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), troponins, and myoglobin in serum, changes in inflammation markers, circulating microRNAs and imaging studies to identify effective biomarkers for use in future clinical trials.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:
  • Aged 18 or older
  • Have a confirmed genetic diagnosis of one of the FSMDs or have a clinical phenotype consistent with one of the FSMDs
  • Be able to travel to the NIH Clinical Center at the NIH for studies
  • Able to commit to multiple 5 day stays at the NIH Clinical Center
  • Established primary care physician
  • Ambulant: able to walk 10 meters or 33 feet without walking aids or orthotics

EXCLUSION CRITERIA:

  • Fail to meet the above inclusion criteria
  • Are unable or unwilling to be examined
  • Adults unable to provide their own consent
  • Have active, on-going medical problems such as (e.g. diabetes, hypothyroidism, pancreatitis, anemia, cancer, renal, hepatic, Pulmonary or cardiac disease) or who have undergone recent surgery (i.e. less than 8 days post-surgery)
  • Pregnant females
  • Currently taking any or a combination of anti-inflammatory drugs, statins or other drugs with known myotoxicity, narcotics
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01851447


Contacts
Contact: Joshua J Zimmerberg, M.D. (301) 496-6571 zimmerbj@mail.nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)    800-411-1222 ext TTY8664111010    prpl@mail.cc.nih.gov   
Sponsors and Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institutes of Health Clinical Center (CC)
University of Massachusetts, Worcester
Investigators
Principal Investigator: Joshua J Zimmerberg, M.D. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  More Information

Additional Information:
Publications:
Responsible Party: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ClinicalTrials.gov Identifier: NCT01851447     History of Changes
Other Study ID Numbers: 130112
13-CH-0112
First Submitted: May 9, 2013
First Posted: May 10, 2013
Last Update Posted: October 19, 2017
Last Verified: July 13, 2017

Keywords provided by National Institutes of Health Clinical Center (CC) ( Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) ):
Muscle
Inflammatory Cytokines
Exercise
Biomarkers
Predictors of Outcome

Additional relevant MeSH terms:
Muscular Dystrophies
Genetic Diseases, Inborn
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases